You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Betof A, Wise-Draper T, He K, et al
783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0783